• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?

作者信息

Ghabri Salah

机构信息

Department of Medical Evaluation-Direction of Evaluation and Access to Innovation-French National Authority for Health, Haute Autorité de Santé, HAS, Saint-Denis, France.

出版信息

Pharmacoeconomics. 2024 Aug;42(8):823-827. doi: 10.1007/s40273-024-01393-9. Epub 2024 May 11.

DOI:10.1007/s40273-024-01393-9
PMID:38733557
Abstract
摘要

相似文献

1
Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?在法国新药基于价值的定价过程中，我们能够或应该使用成本效益阈值吗？
Pharmacoeconomics. 2024 Aug;42(8):823-827. doi: 10.1007/s40273-024-01393-9. Epub 2024 May 11.
2
Convergence of decision rules for value-based pricing of new innovative drugs.新型创新药物基于价值定价的决策规则趋同
Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):209-13. doi: 10.1586/14737167.2015.972374. Epub 2014 Oct 18.
3
[Important to keep the principle of value-based pricing of drugs].[坚持药品价值定价原则很重要]
Lakartidningen. 2009;106(44):2862-4.
4
Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water.基于价值的定价：勿因噎废食。
Pharmacoeconomics. 2018 Jan;36(1):1-3. doi: 10.1007/s40273-017-0566-5.
5
[Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].[法国国家卫生管理局关于健康产品成本效益的意见：结果与展望]
Sante Publique. 2015 Sep-Oct;27(5):691-700.
6
The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?卫生经济评估的效率前沿方法与成本效益阈值及内部参考定价：兼收并蓄？
Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):475-486. doi: 10.1080/14737167.2018.1497976. Epub 2018 Jul 18.
7
The Office of Fair Trading report: a prescription for value-based drug pricing.公平交易办公室报告：基于价值的药品定价方案
J R Soc Med. 2007 May;100(5):216-8. doi: 10.1177/014107680710000510.
8
Grounding Value-Based Drug Pricing in Population Health.基于人群健康的价值导向型药品定价
Clin Pharmacol Ther. 2020 Jun;107(6):1290-1292. doi: 10.1002/cpt.1741. Epub 2020 Jan 17.
9
Value based pricing for NHS drugs: an opportunity not to be missed?英国国家医疗服务体系（NHS）药品的基于价值的定价：一个不容错过的机遇？
BMJ. 2008 Feb 2;336(7638):251-4. doi: 10.1136/bmj.39434.500185.25.
10
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?多适应症定价：理论上可行，但实际中能奏效吗？
Pharmacoeconomics. 2018 Dec;36(12):1407-1420. doi: 10.1007/s40273-018-0716-4.

引用本文的文献

1
Cost-effectiveness of Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy using a French healthcare perspective.从法国医疗保健视角看，马伐卡坦治疗有症状的梗阻性肥厚型心肌病患者的成本效益。
Eur J Health Econ. 2025 Jun 23. doi: 10.1007/s10198-025-01808-0.

本文引用的文献

1
A Framework for the Fair Pricing of Medicines.药品合理定价框架
Pharmacoeconomics. 2024 Feb;42(2):145-164. doi: 10.1007/s40273-023-01325-z. Epub 2023 Dec 8.
2
Challenges of calculating cost-effectiveness thresholds.计算成本效益阈值的挑战。
Lancet Glob Health. 2023 Oct;11(10):e1508. doi: 10.1016/S2214-109X(23)00351-0.
3
Modelling Spillover Effects on Informal Carers: The Carer QALY Trap.建模溢出效应对非正式照顾者的影响：照顾者 QALY 陷阱。
Pharmacoeconomics. 2023 Dec;41(12):1557-1561. doi: 10.1007/s40273-023-01316-0. Epub 2023 Sep 2.
4
The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review.2015 年至 2020 年期间，用于评估中低收入国家卫生干预措施的成本效益阈值：综述。
Value Health. 2022 Mar;25(3):385-389. doi: 10.1016/j.jval.2021.08.014. Epub 2021 Oct 29.
5
Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.健康技术评估中基于价值的价格估算及其不确定性的量化：频率派和贝叶斯方法。
Med Decis Making. 2022 Jul;42(5):672-683. doi: 10.1177/0272989X221079554. Epub 2022 Feb 16.
6
Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates.医疗保健系统所产生的健康边际成本的经验估计：来自国家层面估计的方法学考虑。
Pharmacoeconomics. 2022 Jan;40(1):31-43. doi: 10.1007/s40273-021-01087-6. Epub 2021 Sep 29.
7
Value of a QALY for France: A New Approach to Propose Acceptable Reference Values.法国 QALY 的价值：提出可接受参考值的新方法。
Value Health. 2020 Aug;23(8):985-993. doi: 10.1016/j.jval.2020.04.001. Epub 2020 May 30.
8
Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis.健康总寿命：成本效益分析的一个新健康目标函数。
Value Health. 2020 Jan;23(1):96-103. doi: 10.1016/j.jval.2019.10.014. Epub 2019 Dec 24.
9
Could or Should We Use MCDA in the French HTA Process?我们能够或应该在法国卫生技术评估流程中使用多标准决策分析吗？
Pharmacoeconomics. 2019 Dec;37(12):1417-1419. doi: 10.1007/s40273-019-00846-w.
10
Is rate of return pricing a useful approach when value-based pricing is not appropriate?当基于价值的定价不合适时，回报率定价是一种有用的方法吗？
Eur J Health Econ. 2019 Sep;20(7):945-948. doi: 10.1007/s10198-019-01032-7.